Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women
NCT ID: NCT00369434
Last Updated: 2007-06-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
450 participants
INTERVENTIONAL
2006-06-30
2007-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Desvenlafaxine succinate sustained-release (DVS SR)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body Mass Index (BMI) less than or equal to 40 kg/m2
Other inclusions apply.
Exclusion Criteria
* Myocardial infarction and/or unstable angina within 6 months of screening
* History of seizure disorder
Other exclusions apply.
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Wyeth is now a wholly owned subsidiary of Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Montgomery, Alabama, United States
Peoria, Arizona, United States
Upland, California, United States
Colorado Springs, Colorado, United States
Brooksville, Florida, United States
Inverness, Florida, United States
Miami, Florida, United States
New Port Richey, Florida, United States
Ocala, Florida, United States
St. Petersburg, Florida, United States
Tampa, Florida, United States
Decatur, Georgia, United States
Savannah, Georgia, United States
Boise, Idaho, United States
Idaho Falls, Idaho, United States
Overland Park, Kansas, United States
Louisville, Kentucky, United States
Portland, Maine, United States
Rockville, Maryland, United States
Billings, Montana, United States
Las Vegas, Nevada, United States
Albuquerque, New Mexico, United States
Winston-Salem, North Carolina, United States
Bismarck, North Dakota, United States
Fargo, North Dakota, United States
Cincinnati, Ohio, United States
Eugene, Oregon, United States
Erie, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Wexford, Pennsylvania, United States
Hilton Head Island, South Carolina, United States
Midvale, Utah, United States
Norfolk, Virginia, United States
Richmond, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3151A2-337
Identifier Type: -
Identifier Source: org_study_id